PBRM1 and chordoma: Notably, recent clinical data showed that PBRM1 inactivation may predict benefit from anti-PD-1 checkpoint inhibitors in ccRCC36 and Pbrm1-deficient murine melanomas were more strongly infiltrated by cytotoxic T cells37, suggesting that immune checkpoint inhibitors have the potential of treating chordoma patients with PBRM1 alterations.